Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations.

doi:10.1038/s41598-021-95985-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations.

Scientific reports - 12 Aug 2021

Nguyen Hoai-Nghia, Cao Ngoc-Phuong Thi, Van Nguyen Thien-Chi, Le Khang Nguyen Duy, Nguyen Dat Thanh, Nguyen Quynh-Tho Thi, Nguyen Thai-Hoa Thi, Van Nguyen Chu, Le Ha Thu, Nguyen Mai-Lan Thi, Nguyen Trieu Vu, Tran Vu Uyen, Luong Bac An, Le Linh Gia Hoang, Ho Quoc Chuong, Pham Hong-Anh Thi, Vo Binh Thanh, Nguyen Luan Thanh, Dang Anh-Thu Huynh, Nguyen Sinh Duy, Do Duc Minh, Do Thanh-Thuy Thi, Hoang Anh Vu, Dinh Kiet Truong, Phan Minh-Duy, Giang Hoa, Tran Le Son

Abstract excerpt

Targeted therapy with tyrosine kinase inhibitors (TKI) provides survival benefits to a majority of patients with non-small cell lung cancer (NSCLC). However, resistance to TKI almost always develops after treatment. Although genetic and epigenetic alterations have each been shown to drive resistance to TKI in cell line models, clinical evidence for their contribution in the acquisition of resistance remains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to DNA Copy Number Variations

Share to DNA Methylation

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Liquid Biopsy

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34385540
DOI: 10.1038/s41598-021-95985-6
PMCID: PMC8361064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations.PMID 34385540Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancerSemantic proximity Read ↗

Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice.Semantic proximity Read ↗

The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance predictionSemantic proximity Read ↗

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatmentSemantic proximity Read ↗

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.Semantic proximity Read ↗

Single-Cell RNA Sequencing in Unraveling Acquired Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: New PerspectivesSemantic proximity Read ↗

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.Semantic proximity Read ↗

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Semantic proximity Read ↗

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.